-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13

Benzinga·06/18/2026 16:31:38
Listen to the news
Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.